| Hazard Information | Back Directory | [Clinical Use]
Human monoclonal antibody:
Treatment of advanced gastric cancer or gastrooesophageal junction adenocarcinoma, colorectal
cancer and non-small cell lung cancer (NSLC) | [target]
VEGFR2 | [Drug interactions]
Potentially hazardous interactions with other drugs
Vaccines: risk of generalised infections with live
vaccines - avoid. | [Metabolism]
The metabolism of ramucirumab has not been studied.
Monoclonal antibodies are mainly cleared by catabolism. |
|
|